JOP20230308A1 - 3-(1-أوكسويزويندولين-2-ييل)بيبيريدين-2,6-مشتقات ديون واستخداماتها الطبية - Google Patents

3-(1-أوكسويزويندولين-2-ييل)بيبيريدين-2,6-مشتقات ديون واستخداماتها الطبية

Info

Publication number
JOP20230308A1
JOP20230308A1 JOJO/P/2023/0308A JOP20230308A JOP20230308A1 JO P20230308 A1 JOP20230308 A1 JO P20230308A1 JO P20230308 A JOP20230308 A JO P20230308A JO P20230308 A1 JOP20230308 A1 JO P20230308A1
Authority
JO
Jordan
Prior art keywords
oxoisoindoline
piperidine
medical uses
dione derivatives
hemoglobinopathies
Prior art date
Application number
JOJO/P/2023/0308A
Other languages
Arabic (ar)
English (en)
Inventor
Gary O'brien
Simone Bonazzi
Noel Marie-France Thomsen
Pamela Yf Ting
Janetta Dewhurst
Mooje Sung
Artiom Cernijenko
Jennifer Stroka Cobb
John Ryan Kerrigan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20230308A1 publication Critical patent/JOP20230308A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JOJO/P/2023/0308A 2021-06-03 2023-11-29 3-(1-أوكسويزويندولين-2-ييل)بيبيريدين-2,6-مشتقات ديون واستخداماتها الطبية JOP20230308A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163196422P 2021-06-03 2021-06-03
PCT/IB2022/055131 WO2022254362A1 (en) 2021-06-03 2022-06-01 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof

Publications (1)

Publication Number Publication Date
JOP20230308A1 true JOP20230308A1 (ar) 2023-11-29

Family

ID=82115547

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0308A JOP20230308A1 (ar) 2021-06-03 2023-11-29 3-(1-أوكسويزويندولين-2-ييل)بيبيريدين-2,6-مشتقات ديون واستخداماتها الطبية

Country Status (22)

Country Link
US (2) US12103919B2 (cg-RX-API-DMAC7.html)
EP (1) EP4347580A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520654A (cg-RX-API-DMAC7.html)
KR (1) KR20240013812A (cg-RX-API-DMAC7.html)
CN (1) CN117062811A (cg-RX-API-DMAC7.html)
AR (1) AR126052A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022284366A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024905A2 (cg-RX-API-DMAC7.html)
CA (1) CA3215410A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003561A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024000013A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230614A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000261A (cg-RX-API-DMAC7.html)
EC (1) ECSP24000004A (cg-RX-API-DMAC7.html)
IL (1) IL308094A (cg-RX-API-DMAC7.html)
JO (1) JOP20230308A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023014327A (cg-RX-API-DMAC7.html)
PE (1) PE20240657A1 (cg-RX-API-DMAC7.html)
PY (1) PY2243958A (cg-RX-API-DMAC7.html)
TW (1) TW202306570A (cg-RX-API-DMAC7.html)
UY (1) UY39796A (cg-RX-API-DMAC7.html)
WO (1) WO2022254362A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20250114A1 (es) 2021-06-03 2025-01-16 Chinook Therapeutics Inc Compuestos indol sustituidos y metodos de uso de los mismos
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途
TW202604526A (zh) * 2024-04-29 2026-02-01 美商必治妥美雅史谷比公司 化合物及其治療血色素病變之用途
CN118598797A (zh) * 2024-05-17 2024-09-06 诚达药业股份有限公司 一种手性3-羟基-4-氟哌啶衍生物的合成方法及拆分方法
WO2026002044A1 (zh) * 2024-06-25 2026-01-02 标新生物医药科技(上海)有限公司 含有硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的双功能蛋白降解剂及它们的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012068512A1 (en) 2010-11-18 2012-05-24 Deuteria Pharmaceuticals Llc 3-deutero-pomalidomide
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2014018866A1 (en) 2012-07-27 2014-01-30 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
US20170038387A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
WO2017185031A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
CN110753693A (zh) 2016-12-23 2020-02-04 阿尔维纳斯运营股份有限公司 Egfr蛋白水解靶向嵌合分子和相关使用方法
IL325835A (en) 2016-12-23 2026-03-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
IL300417A (en) 2017-01-26 2023-04-01 Arvinas Operations Inc Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
EP3676268A1 (en) 2017-10-20 2020-07-08 Dana-Farber Cancer Institute, Inc. Heterobifunctional compounds with improved specificityfor the bromodomain of brd4
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019177902A1 (en) 2018-03-10 2019-09-19 Yale University Modulators of btk proteolysis and methods of use
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
US12030892B2 (en) 2018-06-29 2024-07-09 Dana-Farber Cancer Institute, Inc. CRBN modulators
EP3814380A4 (en) 2018-06-29 2022-06-15 Dana Farber Cancer Institute, Inc. BISPECIFIC DEGRADATION PRODUCTS
AU2019294835B2 (en) 2018-06-29 2025-04-17 Dana-Farber Cancer Institute, Inc. Ligands to cereblon (CRBN)
CA3102212A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Immunomodulatory compounds
BR122022012697B1 (pt) * 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
CN113490495B (zh) * 2018-12-03 2024-09-27 达纳-法伯癌症研究公司 Helios的小分子降解剂及其使用方法
JP7874541B2 (ja) 2019-09-16 2026-06-16 ノバルティス アーゲー 接着分解剤及びその使用方法
MX2022004526A (es) * 2019-10-17 2022-07-21 Arvinas Operations Inc Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6.
PH12022551482A1 (en) 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof

Also Published As

Publication number Publication date
WO2022254362A1 (en) 2022-12-08
US20250026736A1 (en) 2025-01-23
CN117062811A (zh) 2023-11-14
TW202306570A (zh) 2023-02-16
AR126052A1 (es) 2023-09-06
BR112023024905A2 (pt) 2024-02-20
ECSP24000004A (es) 2024-02-29
KR20240013812A (ko) 2024-01-30
PY2243958A (es) 2023-01-20
EP4347580A1 (en) 2024-04-10
MX2023014327A (es) 2023-12-13
CL2023003561A1 (es) 2024-06-28
AU2022284366A1 (en) 2023-10-26
UY39796A (es) 2023-07-31
US20230019617A1 (en) 2023-01-19
PE20240657A1 (es) 2024-04-04
CR20230614A (es) 2024-02-01
CO2024000013A2 (es) 2024-01-25
JP2024520654A (ja) 2024-05-24
US12103919B2 (en) 2024-10-01
IL308094A (en) 2023-12-01
CA3215410A1 (en) 2022-12-08
DOP2023000261A (es) 2023-12-29

Similar Documents

Publication Publication Date Title
JOP20220152A1 (ar) مشتقات 3-(5- ميثوكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخداماتها
MX2023014327A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos medicos.
JOP20230218A1 (ar) مشتقات بيرازولو بيريدين واستخداماتها
JOP20250258A1 (ar) مثبطات 2-آزا باي سيكلو هبتان kras
BR0210374A (pt) Amidas de ácido antranìlico com cadeia lateral de heteroarilsulfonila, processos para produção das mesmas, uso das mesmas como medicamento ou agente de diagnóstico, bem como preparações farmacêuticas que contêm as mesmas
MX2025010350A (es) Composiciones y metodos para aumentar la hemoglobina fetal y tratar la anemia de celulas falciformes
EA200702204A1 (ru) Лечение заболеваний соединительной ткани кожи
ATE305469T1 (de) Sulfonsäure- oder sulfonylamino-n-(heteroaralkyl)-azaheterozyklyl midverbindungen
RU2014112324A (ru) Применение органического соединения для лечения синдрома нунан
RU2008138358A (ru) Композиция с фиксированной дозой фитата и цинка
MX2025006619A (es) Compuestos terapeuticos
PT1585513E (pt) Utilizacao de acido docosa-hexaenoico como substancia activa para o tratamento de lipodistrofia
US20160256482A1 (en) Pharmaceutical composition for improving wound healing or prophylactically preventing or inhibiting scar formation
NO20054096L (no) Inhibitor for perioperativ blodsukkerforhoyelse
SG11201806628UA (en) New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
González et al. 4CPS-252 Oral and intravenous iron in the treatment of perioperative anaemia
JP2016011262A (ja) 口腔粘膜疾患の予防または治療用経口製剤
Kashyap et al. Management of Electrocution in a Langur (Semnopithecus entellus)
TH10660C3 (th) สูตรยาสำเร็จรูปชนิดใหม่ (A novel medicament) สำหรับการรักษาการติดเชื้อที่โพรงประสาทฟัน
EA201001301A1 (ru) Применение 1-метил-2-фенилтиометил-3-карбэтокси-4-диметиламинометил-5-окси-6-броминдола и его солей для профилактики и/или лечения инфекционных заболеваний животных вирусного генеза
ATE532512T1 (de) Isoniazid-vermittelte heilung von wunden und geschwüren